Lymphocyte aggregates persist and accumulate in the lungs of patients with idiopathic pulmonary fibrosis

Nevins W Todd1,2, Rachael G Scheraga1,3, Jeffrey R Galvin1,4, Aldo T Iacono1, E James Brit1, Irina G Luzina1,2, Allen P Burke5,*, Sergei P Atamas1,2,*
1 Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; 2 Baltimore VA Medical Center, Baltimore, MD, USA; 3 Critical Care Medicine Department, National Institutes of Health, Bethesda, MD, USA; 4 Department of Diagnostic Radiology, University of Maryland School of Medicine, Baltimore, MD, USA; 5 Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA
*These authors contributed equally to this work

Background: Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with no known effective therapy. It is often assumed, but has not been objectively evaluated, that pulmonary inflammation subsides as IPF progresses. The goal of this work was to assess changes in the degree of inflammatory cell infiltration, particularly lymphocytic infiltration, over the duration of illness in IPF.

Methods: Sixteen patients with confirmed IPF were identified in patients whom surgical lung biopsy (SLB) was performed in early disease, and in patients whom lung transplantation was subsequently performed in end stage disease. A numerical scoring system was used to histologically quantify the amount of fibrosis, honeycomb change, fibroblastic foci, and lymphocyte aggregates in each SLB and lung explant tissue sample. Analyses of quantitative scores were performed by comparing paired, matched samples of SLB to lung explant tissue. Results: Median time [1st, 3rd quartiles] from SLB to lung transplantation was 24 [15, 29] months. Histologic fibrosis and honeycomb change were more pronounced in the explant samples compared with SLB (P<0.001 and P<0.01, respectively), and most notably, higher numbers of lymphocyte aggregates were observed in the explant samples compared to SLB (P=0.013). Immunohistochemical analyses revealed abundant CD3+ (T lymphocyte) and CD20+ (B lymphocyte) cells, but not CD68+ (macrophage) cells, within the aggregates.

Conclusion: Contrary to the frequent assumption, lymphocyte aggregates were present in greater numbers in advanced disease (explant tissue) compared to early disease (surgical lung biopsy). This finding suggests that active cellular inflammation continues in IPF even in severe end stage disease.

Keywords: idiopathic pulmonary fibrosis, inflammation, lymphocyte aggregates

Introduction

Inflammation in the lung is a consistent finding in patients with idiopathic interstitial pneumonia, a group of pulmonary diseases characterized by distinct clinical, physiologic, radiologic, and pathologic findings.1 The most common and severe form of idiopathic interstitial pneumonia is idiopathic pulmonary fibrosis (IPF). The pathologic hallmark of IPF is a pattern of lung injury termed usual interstitial pneumonitis (UIP), which consists histologically of a combination of inflammatory cell infiltration, loss of normal epithelium, clusters of fibroblasts or myofibroblasts (fibroblastic foci), extracellular matrix deposition (fibrosis), and the formation of small lung cysts (honeycomb change).2,3 IPF is a severely debilitating and fatal lung disease, with an overall median survival of approximately 3 years, with no proven effective therapy, and with lung transplantation remaining the only viable intervention in end stage disease.3
Although the precise role of inflammation in IPF remains controversial, there appears to be little doubt that inflammation is consistently present in the lungs of these patients. From the earliest descriptions of patients with pulmonary fibrosis, infiltration of inflammatory cells in the lung parenchyma, particularly lymphocytes, was a universally observed histologic finding.\textsuperscript{4,5} and almost all patients currently diagnosed with IPF will manifest a mild to moderate degree of inflammatory cell infiltration in the lung.\textsuperscript{1–3,6,7} In addition to the presence of inflammatory cells in IPF, increased levels of numerous pro-inflammatory cytokines, chemokines, and cell surface molecules have been extensively documented over the last four decades in animal models and patients with pulmonary fibrosis.\textsuperscript{8–11}

It has been suggested that patients with IPF have active inflammatory cell infiltration early in the course of disease, but subsequently have decreasing amounts of inflammation as the disease progresses over time, as fibrosis ensues, and as the inflammatory process becomes “burned out.”\textsuperscript{12–14} This concept of inflammation representing an early stage of IPF and disappearing at later stages of disease may seem plausible, but the degree of inflammatory cell infiltration at different time points in IPF has never been objectively evaluated.

The goal of the current study was to histologically assess the degree of inflammatory cell infiltration as IPF progresses. We identified a cohort of 16 patients with IPF in whom a surgical lung biopsy (SLB) was performed as part of the initial diagnostic evaluation (early disease) and in whom lung transplantation (with available lung explant tissue) was performed at a later time point due to the development of end stage lung disease. By performing a detailed qualitative and quantitative histologic assessment on each SLB and explant tissue sample, we sought to determine the degree of inflammatory cell infiltration, particularly lymphocytic cellular infiltration, in IPF over the duration of patient disease.

**Patients and methods**

**Patients**

This study was reviewed and approved by the University of Maryland Institutional Review Board. One hundred fifty seven patients underwent lung transplantation at the University of Maryland from 2002 through 2011, and from this group, we identified 16 patients with IPF in whom a SLB was performed early in their illness as part of the initial diagnostic evaluation and in whom lung transplantation (with removal of the native lung [lung explant]) was performed subsequently due to the development of end stage lung disease. Initial review of the clinical, physiologic, radiologic, and pathologic findings indicated a diagnosis of IPF in each patient based on the recent consensus statement for IPF.\textsuperscript{1}

Patient demographics, clinical history and physical exam findings, pulmonary function tests, and computed tomography images of the chest were reviewed in detail and findings documented for each patient. The time interval from SLB to lung transplantation was recorded for each patient.

**Histologic evaluation**

Following the initial chart review, a detailed qualitative and quantitative histologic evaluation was performed in each SLB and explant sample by a clinical pathologist (APB) with extensive experience in the histology of diffuse parenchymal lung disease. The presence and severity of the following findings were assessed as follows: geographic heterogeneity, lymphocytic aggregates, foci of smooth muscle bundles, fibroblastic foci, organizing pneumonia, pigmented macrophages, hyaline membranes, parenchymal fibrosis, and cystic spaces (honeycombing). A definitive pathologic diagnosis was rendered on each tissue sample according to standard criteria.\textsuperscript{1–3}

Quantitative assessments were performed on the upper and lower lobe of each SLB and lung explant tissue sample for the following characteristics: (1) histologic fibrosis and honeycomb change, which were scored based on percentage involvement of the tissue sample (none, 1%–10%, 11%–25%, 26%–50%, >50%), and (2) fibroblastic foci and lymphocyte aggregates, which were scored as absolute numerical counts observed in total lung tissue and then standardized to 1 cm\textsuperscript{2} of lung tissue. Groups of lymphocytes were counted as an aggregate if \( \geq 100 \) \( \mu \text{m} \) in diameter. To assist with quantitative scoring of samples, all sections were scanned in their entirety into a digital pathology system (Aperio Technologies, Vista, CA, USA), which allowed for analyzing slides at any magnification up to the highest magnification scanned.

Analyses of quantitative scores were performed by comparing paired, matched samples of SLB to lung explant samples. Specifically, each score for upper lobe SLB was compared to upper lobe explant, and each score for lower lobe SLB compared to lower lobe explant, for each individual patient. Our comparison analysis was ultimately limited by the number of SLBs available, due to the inherent risks of obtaining numerous SLB samples from IPF patients. All SLB scores (upper and lower lobe) were compared to all explant samples (upper and lower lobe) in a paired, matched format to provide the best representation of the histologic features in the entire lung.
Immunohistochemical evaluation

Immunohistochemistry was performed to further characterize the lymphocytic aggregates. For CD3, CD20, CD68, and Ki-67, pre-diluted monoclonal rabbit (CD3, Ki-67) and mouse (CD20, CD68) antibodies (Ventana, Tucson, AZ, USA) were utilized with an automated immunostainer and the Ultraview indirect biotin-free diaminobenzidine detection kit (BenchMark, Ventana, Tucson, AZ, USA). Polyclonal rabbit antibody against cleaved caspase 3 (EMD Millipore, Billerica, MA, USA) was used to histologically assess cellular apoptosis.

Following immunohistochemical staining for CD3 and CD20, morphometric analysis was performed to further assess the degree of CD3+ and CD20+ cell infiltration in tissue samples. Image thresholding and area measurements were performed using the ImageJ program\(^\text{13}\) to determine total surface tissue area, percentage of tissue area occupied by CD3+ and CD20+ cells, and the ratio of tissue area occupied by CD3+ and CD20+ cells, respectively.

Statistical analyses

Differences between paired matched samples were analyzed by nonparametric Wilcoxon signed rank test (Graph Pad Software, La Jolla, CA, USA) or by paired two tailed Student's \(t\)-test. Differences at \(P < 0.05\) were considered significant.

Results

Patient characteristics

The patient cohort (n = 16) consisted of ten males and six females. There were 12 Caucasians and four African-Americans, and the median age [1st, 3rd quartiles] was 62 [57,66] years. Ten patients were lifelong nonsmokers, and no patient was an active smoker at the time of SLB or lung transplantation. For the entire cohort, pulmonary function testing indicated a moderately severe restrictive ventilatory defect, demonstrated by a forced vital capacity of 59 [44,69] percent predicted, and a severe abnormality in gas transfer, demonstrated by a diffusing capacity for carbon monoxide of 45 [34,55] percent predicted. Median time from SLB to subsequent lung transplantation in the cohort was 24 [15,29] months.

Detailed histologic analysis confirmed the pathologic pattern of UIP on both SLB and lung explant tissue in each patient. Figure 1 shows low and high magnification sections of the SLB (upper panels) and lung explant (lower panels) from a typical patient. The presence of UIP in conjunction with the clinical, physiologic, and radiographic findings confirmed the diagnosis of IPF in all patients.

Histologic analysis of fibrosis and honeycomb change

The percentage involvement of histologic fibrosis and honeycomb change was assessed in each SLB and explant tissue sample. Analyses of scores were performed by comparing paired, matched samples of SLB to lung explant samples. Specifically, scores for upper lobe SLB were compared to upper lobe explant, and scores for lower lobe SLB compared to lower lobe explant, for each individual patient. As shown in Figure 2, there was more histologic fibrosis and honeycomb change in the explant samples compared with SLB across the cohort (\(P < 0.001\) and \(P < 0.01\), respectively, Wilcoxon signed rank test). These findings were consistent with the known progression of UIP in patients with IPF.

Histologic analysis of fibroblastic foci and lymphocyte aggregates

The absolute number of fibroblastic foci and lymphocyte aggregates was counted in each SLB and explant sample, and then standardized to 1 cm\(^2\) of lung tissue. Analyses of counts were performed by comparing paired, matched samples of SLB to lung explant samples for each individual patient (upper lobe SLB to upper lobe explant and lower lobe SLB to lower lobe explant). For fibroblastic foci, there were equal numbers found in SLB and explant samples across the cohort (\(P = 0.74\), Wilcoxon signed rank test).

For lymphocyte aggregates, as shown in Figure 3, there were more lymphocyte aggregates found in the explant samples compared to SLB. Figure 3A shows histology from a typical patient demonstrating selected aggregates of mononuclear cells \(\geq 100 \mu m\) in diameter which were counted as lymphocyte aggregates. Figure 3B shows changes in the numbers of aggregates in the SLB and explant samples, and most notably, higher numbers of lymphocyte aggregates were observed in the explant samples compared to SLB across the cohort (\(P = 0.013\), Wilcoxon signed rank test). This finding disputed the frequent assumption that inflammation decreases as disease progression occurs in patients with IPF.

Immunohistochemistry was used to further characterize the composition of the lymphocyte aggregates, as shown in Figure 4 from a lung explant sample. The mononuclear cell aggregates consisted of CD3+ (T lymphocyte) and CD20+ (B lymphocyte) cells. Staining for CD68 showed very few CD68+ monocytes or macrophages within the lymphocyte aggregates, but did demonstrate CD68+ cells within small airways, alveolar spaces, and honeycombed cysts.
As can also be seen in Figure 4, CD20+ cells were predominantly present in cohesive, focal clusters, whereas CD3+ cells were present not only in cohesive clusters, but also diffusely throughout the tissue as single cells or small groups of a few cells. Morphometric analysis was performed to further assess the degree of CD3+ and CD20+ cell infiltration in five explant tissue samples. There was a greater mean percentage of tissue area occupied by CD3+ cells (14.0 ± 7.4) than by CD20+ cells (7.2 ± 3.9) (P = 0.016, paired two tailed Student’s t-test). There was also a remarkably consistent ratio of the percentage area occupied by CD3+ and CD20+ cells, respectively, with a CD3+/CD20+ ratio of 2.0 ± 0.4 amongst the samples.

Staining for Ki-67, a nuclear antigen expressed during all active phases of the cell cycle and a marker of cellular proliferation, showed only minimal positivity within the lymphocyte aggregates. Staining for cleaved caspase 3, a marker for cellular apoptosis, showed no positive staining within the lymphocyte aggregates, but did show a few positive staining mesenchymal cells in the lung parenchyma, and a few positive staining granulocytes in small pulmonary vessels (data not shown). These results indicate the presence of nonproliferating, nonapoptotic lymphocytes within the aggregates.

**Discussion**

Our results indicate that as disease progression occurred in patients with IPF, histologic fibrosis and honeycomb change worsened as was expected, but additionally, and contrary to current opinion, aggregates of lymphocytes progressively accumulated in the lungs as well. To our knowledge, this is the first study which has objectively evaluated histologically the degree of lymphocytic infiltration in IPF over the duration of patient disease.

These findings are particularly important due to their divergence from the current dogma which states...
that inflammation decreases, and may even disappear (become “burned out”), as disease progression occurs in IPF.\textsuperscript{5,12–14} Furthermore, a prevailing hypothesis has been put forward by many stating that inflammation has no role in the mechanisms or pathogenesis of IPF.\textsuperscript{16–18} The basis of these opinions most likely results from (1) a shift in IPF focus away from inflammation and towards aberrant wound healing, and (2) the ineffectiveness of traditional anti-inflammatory therapies, which will be discussed further below. The novelty of our study is the objective evaluation of inflammatory cell

![Lymphocyte aggregates](image1.png)

**Figure 3** Lung explant histology (A) from a typical patient demonstrating selected aggregates of mononuclear cells $\geq 100$ $\mu$m in diameter (arrowheads) which were counted as lymphocyte aggregates. A scatter plot (B) composed of numerical counts of lymphocyte aggregates compares upper lobe SLB to upper lobe explant (unmarked ends) and lower lobe SLB to lower lobe explant (circled ends) for each individual patient.  
**Note:** There were more lymphocyte aggregates in the explant samples compared to SLB across the cohort ($P = 0.013$, Wilcoxon signed rank test).

**Abbreviation:** SLB, surgical lung biopsy.

![Histologic fibrosis and honeycomb change](image2.png)

**Figure 2** Stacked column graph showing the degree of histologic fibrosis and honeycomb change in SLB and explant samples, scored by percentage involvement of tissue: 1 (none), 2 (1%–10%), 3 (11%–25%), 4 (26%–50%), and 5 (>50%).

**Notes:** There was more histologic fibrosis and honeycomb change in the explant samples compared to SLB across the cohort ($P < 0.001$ and $P < 0.01$ respectively, Wilcoxon signed rank test).

**Abbreviation:** SLB, surgical lung biopsy.
The precise etiology of IPF remains unknown despite four decades of intense research. Although numerous mechanisms have been explored, the most consistently studied mechanism has been the role of inflammation. Despite the universal presence of numerous pro-inflammatory cells, cytokines, chemokines, and cell surface molecules in these patients, the importance of inflammation has been recently challenged. One of the major arguments often cited for a noncausal role for inflammation is the ineffectiveness of anti-inflammatory therapies, particularly corticosteroids, in improving survival in patients with IPF. However, it is important to note that resistance to corticosteroids does not always equate to the lack of important inflammatory mechanisms. There are several clinical pulmonary and nonpulmonary diseases in which inflammation is well established as the fundamental mechanism, but in which conventional anti-inflammatory therapy is poorly or completely ineffective. One such example for this discrepancy is oxidative stress promoting corticosteroid resistant inflammation in the lung, a particularly plausible concept in pulmonary diseases given the uniquely oxygenated environment of the lung, and the numerous observations implicating oxidative stress in mechanisms of pulmonary fibrosis. Continued efforts to understand the precise role of inflammation and possible mechanisms of corticosteroid resistant inflammation remain warranted in IPF patients.

Despite some limitations, such as a relatively small sample size and observational nature of our measure-

Figure 4 Immuno-
ments, the strength of our work is a unique set of matching lung tissue samples consisting of a surgical lung biopsy obtained early in the course of disease and lung explant tissue obtained at the time of end-stage disease. The ability to obtain matched samples such as these in patients with IPF is relatively infrequent due to appropriate caution in proceeding with surgical lung biopsy in IPF patients, and the inherent and frequent obstacles to successful lung transplantation. Given the well known heterogeneity of the lung in IPF, we compared all paired, matched samples (upper lobe SLB to upper lobe explant and lower lobe SLB to lower lobe explant) in the statistical analysis to achieve the most scientifically valid comparison, and to provide the best representation of the histologic features in the entire lung. The numerical assessment of histological changes in these matched samples allowed for our novel observation that greater numbers of lymphocyte aggregates were present in advanced disease compared with early disease in patients with IPF. Further mechanistic studies are warranted to determine the precise role of these infiltrating lymphocytes.

Acknowledgments
Supported by Department of Veterans Affairs Merit Award 5I01CX000107 and National Institutes of Health – National Heart, Lung, and Blood Institute Grant 1R21HL106196 (both to SPA).

Disclosure
The authors report no conflicts of interest in this work.

References
1. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, Jun 2001 and by the ERS Executive Committee, Jun 2001. Am J Respir Crit Care Med. 2002;165(2):277–304.
2. Myers JL, Katzenstein AL. Beyond a consensus classification for idiopathic interstitial pneumonias: progress and controversies. Histopathology. 2009;54(1):90–103.
3. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
4. Scadding JG, Hinson KF. Diffuse fibrosing alveolitis (diffuse interstitial fibrosis of the lungs). Correlation of histology at biopsy with prognosis. Thorax. 1967;22(4):291–304.
5. Crystal RG, Fulmer JD, Roberts WC, Moss ML, Line BR, Reynolds HY. Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med. 1976;85(6):769–788.
6. Katzenstein AL, Zisman D, Litzky L, Nguyen B, Kotloff R. Usual interstitial pneumonia: histologic study of biopsy and explant specimens. Am J Surg Pathol. 2002;26(12):1567–1577.
